ORIGINAL RESEARCH
Published on 02 Aug 2022
Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
![Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer](https://www.frontiersin.org/files/myhome article library/837963/837963_Thumb_400.jpg)
doi 10.3389/fonc.2022.837963
- 1,762 views
- 3 citations